Formulation Development and Evaluation of Poly herbal Formulation for Pulmonary Tuberculosis

Abstract

Background: Globally tuberculosis is an extensive health issue and main query with the available treatment is adverse effects and drug resistance. Since ages, Ayurvedic and herbal medicines have to struggle with modern medicines, which are demonstrate to be immediate-acting, strong and newline potent. The evolution in herbal drug formulations and its standardization are intricate and associate with a number of trials. Aim: The present study aims to design, development of an anti-tubercular polyherbal chewable tablets and its standardization and in-vitro anti-tubercular activity. Methods: Based on the literature survey, four anti-tubercular plant extracts i.e. Glycyrrhiza glabra (Yastimadhu), Piper longum (Pippali), Curcuma longa (Haridra), and Adhatoda vasica (Vasaka) were selected for the development of polyherbal chewable tablet formulation. 32 factorial design newline was applied for formula optimization. Tablets were prepared by wet granulation method and quantitatively evaluated by HPLC. In-vitro anti-mycobacterial activity was performed by agar well diffusion method and MGIT BACTECH. Results: Extracts were authenticated by qualitative HPTLC fingerprinting in comparison with suitable raw herbs and phytomarkers. The pre-compression and post- compression studies showed that the formulation F5 showed better taste and good results among all the formulations designed. Quantification by HPLC revealed that polyherbal chewable tablet showed 1.03 % of glycyrrhizin, 0.44 % of piperine, 1.37 % of curcumin, and 0.086 % of vasicine content. Polyherbal chewable newline tablet were stable throughout the stability study (40ºC 2ºC and 75 % 5 % RH). Polyherbal newline chewable tablet showed maximum 22mm to 23mm of zone of inhibition on Mycobacterium newline smegmatis. In-vitro activity on Mycobacterium tuberculosis and MDR tuberculosis strain showed no growth at tested sample compared with positive and negative control.